The offering was priced at a meaningful discount to the prior close, signaling urgency to raise capital despite positive clinical data. The ~$182M quarterly cash burn rate suggests the ~$694M cash balance provides roughly 3-4 quarters of runway, making this raise critical to fund the casdatifan program through key catalysts. Monitor the stock for continued selling pressure as the 60-day lock-up on insiders and the 30-day overallotment period expire.
Price Chart
Executive Summary
Arcus Biosciences priced a $250M underwritten public offering of 14,285,715 common shares at $17.50 per share, an 8.4% discount to the prior close of $19.10. The offering follows a preliminary Q3 2026 cash balance of ~$694M (down from $876M at Q2 end) and positive casdatifan data presented on October 20, 2026. Net proceeds of ~$234.5M will fund R&D, primarily the casdatifan program, extending the cash runway into 2027.
Key Facts
- Offering of 14,285,715 shares at $17.50/share, an 8.4% discount to the $19.10 prior close
- Total gross proceeds of $250,000,013; net proceeds ~$234.5M after underwriting discounts and estimated expenses
- Underwriters have a 30-day option to purchase up to 2,142,857 additional shares
- Pro forma diluted share count increases from 127,018,631 to 141,304,346 (11.2% dilution), or 143,447,203 if the overallotment is exercised (12.9% dilution)
- New investors face immediate dilution of $12.56 per share (72% of the offering price)
- Preliminary Q3 2026 cash balance of ~$694M, down from $876M at Q2 end and $1.01B at year-end 2025, reflecting a ~$182M quarterly burn rate
- Proceeds will fund R&D, primarily the expansion and acceleration of the casdatifan clinical program
- Positive casdatifan data from the ARC-20 study presented on October 20, 2026, showed a 50% cORR in first-line combination and 36% cORR in late-line monotherapy
Financial Impact
11.2% dilution to existing shareholders (12.9% if overallotment exercised); $250M gross capital raise at an 8.4% discount to market
Risk Factors
- Immediate 11.2% dilution to existing shareholders with potential for further dilution if the overallotment is exercised
- Cash burn rate of ~$182M/quarter may require additional capital raises within 12 months despite this offering
- The 8.4% discount to the prior close could signal weak demand or a distressed capital need
- Clinical-stage biotech risk: casdatifan remains unapproved and subject to regulatory and trial outcome risks
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-428916 |
| Document: d117931dexfilingfees.htm | 0001193125-26-428916 |
| Document: 0001193125-26-428916-index-headers.html | 0001193125-26-428916 |
| Document: 0001193125-26-428916-index.html | 0001193125-26-428916 |
| Document: 0001193125-26-428916.txt | 0001193125-26-428916 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $18.47 | awaiting T+1 | — | $18.54 (−0.38%) |
Oct 22, 2026 3d ago | 424B5 | $19.36 | awaiting T+1 | — | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 424B5 | $19.36 $18.54 | ▲ +4.24% | ▲ +3.71% | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 8-K | $19.36 $18.54 | ▼ −4.24% | ▼ −3.71% | $18.54 (−4.24%) |
Oct 20, 2026 6d ago | 8-K | $23.75 $19.10 | ▼ −19.58% | ▼ −20.10% | $18.54 (−21.94%) |
Jul 9, 2026 15w ago | 144 | $28.92 $28.07 | ▼ −2.94% | ▼ −2.17% | $18.54 (−35.89%) |
Apr 21, 2026 26w ago | DEFA14A | $26.62 $25.13 | ▼ −5.60% | ▼ −5.20% | $18.54 (−30.35%) |
Apr 20, 2026 27w ago | 8-K | $22.74 $24.52 | ▼ −7.83% | ▼ −8.48% | $18.54 (+18.47%) |
Apr 8, 2026 28w ago | 144 | $23.28 $22.34 | ▼ −4.04% | ▼ −3.98% | $18.54 (−20.36%) |
Feb 25, 2026 34w ago | 8-K | $19.54 $20.37 | ▲ +4.25% | ▲ +4.73% | $18.54 (−5.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers